Humanigen Inc (OTCMKTS:HGEN) received an award from the American Society of Hematology (ASH) after presenting an abstract at the organization's annual meeting last week.
The company won a 2019 ASH Abstract Achievement Award for one of its two presentations, which showed results from a study of its drug candidate lenzilumab.
The drug, a monoclonal antibody, works to improve CAR-T, a new approach to cancer therapy involving altered T cells. Humanigen said a xenograft model for relapsed acute lymphoblastic leukemia showed improved overall survival compared to another treatment called CART19.
READ: Humanigen to present abstracts highlighting its glioblastoma treatments at industry conference
Specifically, it works to neutralize the protein GM-CSF using activated CAR-T cells, a modified form of the white blood cell subset.
"It is gratifying to receive recognition for the second year in succession that we have presented GM-CSF -related data for the pioneering work that we are conducting to make CAR-T therapy potentially more efficacious and safer through GM-CSF neutralization," CEO Cameron Durrant said in a statement. "We are looking forward to bringing lenzilumab into the clinic as we begin dosing patients in ZUMA-19 in 2020 with our partner, Kite Pharma."
The Burlingame, California-based company plans to work with Kite to study lenzilumab as a potential treatment for patients with relapsed diffuse large B-cell lymphoma.
Kite, owned by Gilead Sciences Inc (NASDAQ:GILD), has developed the drug Yescarta, which lenzilumab will be paired with, in the study.
Contact Andrew Kessel at email@example.com
Follow him on Twitter @andrew_kessel